Actively Recruiting
Observational Study Comparing Caris Chromoseq to Standard Tests for Blood Cancers Including AML, MDS, and MPN
Led by Caris Science, Inc. · Updated on 2026-07-02
300
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are collecting clinical data on patients with blood cancers including acute myeloid leukemia AML, myelodysplastic syndrome MDS, and myeloproliferative neoplasms MPN who receive the Caris Chromoseq assay. This assay is designed to provide detailed whole genome profiling and risk stratification, and the study aims to compare its performance to standard tests like conventional cytogenetics, FISH, and NGS analysis. The study hypothesizes that Caris Chromoseq may offer advantages in risk assessment, ease of use, and turnaround time. Participants in this observational study will be those diagnosed with AML, MDS, or MPN who have their physicians order the Caris Chromoseq assay along with standard cytogenetic, FISH, and NGS tests within the same timeframe. The study will include approximately 300 subjects in the United States. Data collection will focus on how Caris Chromoseq compares to the conventional testing methods during the course of routine clinical care. Throughout the study, researchers will gather clinical data related to the genetic profiling from Caris Chromoseq and compare it to the results from conventional tests. The main outcome measure is the performance comparison over a two-year period. Participants will be monitored through their usual clinical visits, and data on risk stratification and test turnaround times will be recorded. The study is expected to continue until July 2029.
CONDITIONS
Brief Title
Caris Chromoseq Data Collection
Research Team
M
Mary Baker
H
Harshita Mittal
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here